FidoCure® Veterinary Team Blog

Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates from our team of experts and advisors

Posts by:

Christina K. Lopes

A Year of Breakthroughs: A look back at 2023

We would like to express our heartfelt gratitude to our veterinary community as we come to the close of the year. Together, we have made a tremendous impact by enabling precision medicine to nearly 5,000 pet dogs battling cancer. 

Read More

Fireside Chat with Dr. Len Lichtenfeld - Former Deputy Chief Medical Officer of American Cancer Society

Exclusive fireside chat with a distinguished trio of cancer experts: Dr. Len Lichtenfeld former Deputy Chief Medical Officer for the American Cancer Society (and FidoCure Scientific Advisory Board Member) with Dr. Gerry Post, Chief Medical Officer, FidoCure and Christina Lopes, CEO, FidoCure.
Hear first-hand about their 8-year journey together in the fight against cancer on both ends of the leash.
Read More

No Dog Left Behind: Plan of Action to Address Drug Shortages

As you are likely aware, global supply chain issues are causing shortages of crucial raw drug ingredients needed to produce targeted therapy medications. These shortages are having a significant impact on the veterinary compounding pharmacy industry, and we know that you, your patients and pet parents are feeling the effects.

We want you to know that the FidoCure® team shares your sense of urgency and we are working hard to ensure that no dog is left without the cancer treatments it needs.

Providing access to life-saving therapies is one of our core values, and we are committed to putting you and your patients first.

Read More

DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy. 

© Copyright 2018-2022 OHC, All rights reserved